Roquinimex

Cat. No.: HY-13743
CAS No.: 84088-42-6
Molecular Formula: C₁₈H₁₆N₂O₃
Molecular Weight: 308.33
Target: TNF Receptor
Pathway: Apoptosis
Storage: Powder
        -20°C  3 years
        4°C    2 years
In solvent
        -80°C  2 years
        -20°C  1 year

SOLVENT & SOLUBILITY

In Vitro
DMSO ≥ 83.3 mg/mL (270.17 mM)
"≥" means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Concentration</th>
<th>Mass</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mg</td>
<td>5 mg</td>
</tr>
<tr>
<td>1 mM</td>
<td>3.2433 mL</td>
<td>16.2164 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.6487 mL</td>
<td>3.2433 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.3243 mL</td>
<td>1.6216 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha. IC50 value: Target: TNF alpha.
Prophylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3].

REFERENCES
